Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 11/20 | 0.63 |
| ▸ | CNR2 | P34972 | 7/20 | 0.56 |
| ▸ | MEN1 | O00255 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | EGLN1 | Q9GZT9 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1218512 | 0.93 | CNR1 (0.55) | CNR1CNR2MEN1KMT2AL3MBTL1 | |
| SCHEMBL13689146 | 0.91 | CNR1 (0.52) | CNR1CNR2MEN1KMT2AL3MBTL1 | |
| SCHEMBL1217864 | 0.89 | CNR1 (0.55) | CNR1CNR2MEN1KMT2AALDH1A1 | |
| SCHEMBL12884642 | 0.87 | CNR1 (0.56) | CNR1CNR2MEN1KMT2AL3MBTL1 | |
| SCHEMBL1218827 | 0.87 | CNR1 (0.56) | CNR1CNR2MEN1KMT2AL3MBTL1 | |
| SCHEMBL1217140 | 0.86 | CNR1 (0.57) | CNR1CNR2 | |
| SCHEMBL1218497 | 0.86 | MEN1 (0.50) | CNR1CNR2MEN1KMT2AL3MBTL1 | |
| SCHEMBL13690899 | 0.83 | CNR1 (0.62) | CNR1CNR2 | |
| SCHEMBL1218334 | 0.82 | L3MBTL1 (0.51) | CNR1CNR2MEN1KMT2AL3MBTL1 | |
| SCHEMBL27823743 | 0.82 | L3MBTL1 (0.51) | CNR1CNR2MEN1KMT2AL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110028447-A1 | INDAZOLE DERIVATIVES | PFIZER INC. | 2011-02-03 | — | — | US | claimed |
| EP-2265335-A1 | INDAZOLE DERIVATIVES | Pfizer Inc. (US) | 2010-12-29 | — | — | EP | claimed |
| WO-2009106982-A1 | INDAZOLE DERIVATIVES | PFIZER INC. (US) | 2009-09-03 | — | — | WO | claimed |
| US-20110028447-A1 | INDAZOLE DERIVATIVES | PFIZER INC. | 2011-02-03 | — | — | US | disclosed |
| US-20110028447-A1 | INDAZOLE DERIVATIVES | PFIZER INC. | 2011-02-03 | — | — | US | disclosed |
| US-20110028447-A1 | INDAZOLE DERIVATIVES | PFIZER INC. | 2011-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110028447-A1 | INDAZOLE DERIVATIVES | CNR1, CNR2, GPR119 | CNR1 1/4885CNR2 2/4885MEN1 1806/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.